immunomodulator market growth, immunomodulator market forecast, immunomodulator market trends, immunomodulator market share, immunomodulator market demand, immunomodulator market size
What is the current market size and future outlook for the immunomodulator market?
The immunomodulator market size has grown strongly in recent years. It will grow from $219.94 billion in 2024 to $237.71 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to healthcare infrastructure development, increased awareness among patients, the aging population, increasing incidence of autoimmune diseases, and the introduction of biologic drugs.
The immunomodulator market size is expected to see strong growth in the next few years. It will grow to $319.67 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growing patient preference for non-invasive, regulatory approvals and guidelines, the extent of health insurance coverage for immunomodulatory treatments, the number and progress of immunomodulatory drugs, and government healthcare expenditure. Major trends in the forecast period include advancements in biotechnology and immunotherapy, the number and progress of immunomodulatory drugs in the research and development pipeline, advances in technology, the trend towards personalized medicine, and advancements in immuno-oncology.
Get Your Free Sample of The Global Immunomodulator Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15591&type=smp
What are the key drivers behind the rapid expansion of the immunomodulator market?
The rise in chronic diseases is expected to propel the growth of the immunomodulator market. Chronic diseases are long-lasting medical conditions that typically develop gradually over time and persist for extended periods, often lasting for years or even a lifetime. Chronic diseases are becoming more common due to a multitude of interconnected variables, such as an aging population, lifestyle decisions, genetic predispositions, and the accessibility and infrastructure of healthcare. Immunomodulators provide valuable therapeutic options for managing chronic diseases by modulating immune responses, reducing inflammation, preventing organ rejection, enhancing immune surveillance, and improving symptom control. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. There were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Therefore, the rise in chronic diseases is driving the growth of the immunomodulator market.
What is the segmentation for the immunomodulator market?
The immunomodulator market covered in this report is segmented –
1) By Product Type: Immunosuppressants, Immunostimulants, Other Product Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Oncology, Respiratory, Human Immunodeficiency Virus, Other Applications
4) By End-User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Immunosuppressants: Corticosteroids, Calcineurin Inhibitors (Tacrolimus, Cyclosporine), Mtor Inhibitors ( Sirolimus, Everolimus), Antimetabolites ( Azathioprine, Methotrexate), Biologic Immunosuppressants (Monoclonal Antibodies Like Rituximab), Janus Kinase (Jak) Inhibitors, T-Cell Inhibitors, Other Immunosuppressive Agents
2) By Immunostimulants: Cytokine And Growth Factor-Based Immunostimulants ( Interferons, Interleukins), Monoclonal Antibodies For Immune Stimulation, Vaccines ( Cancer Vaccines, Preventive Vaccines), Adjuvants And Immune Modulatory Agents, Immunostimulatory Agents For Autoimmune Diseases, Toll-Like Receptor (Tlr) Agonists, Nucleic Acid-Based Immunostimulants ( Dna Or Rna Vaccines)
3) By Other Product Types: Biologics ( Fusion Proteins, Immune Checkpoint Inhibitors), Small Molecule Immunomodulators, Immunotherapy Drugs, Stem Cell-Based Immunomodulators, Immuno-Oncology Drugs, Probiotics And Other Natural Immunomodulatory Agents
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/immunomodulator-global-market-report
Who are the most influential companies in the immunomodulator market?
Major companies operating in the immunomodulator market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Applied Molecular Genetics Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Horizon Therapeutics plc, Incyte Corporation, Ipsen SA, Kyowa Kirin Co. Ltd., Amicus Therapeutics Inc.
What are the most influential trends expected to drive the immunomodulator market forward?
Companies operating in the immunomodulator market are focused on the development of non-immunosuppressive products to address the growing demand for treatments that offer targeted immune modulation without compromising the body’s overall immune function. Non-immunosuppressive refers to treatments or substances that do not suppress or weaken the immune system’s response. For instance, in February 2024, Nuvig Therapeutics, Inc., a US-based biotechnology company, initiated early-stage clinical trials for NVG-2089, a next-generation immune modulator. NVG-2089 is a proprietary product designed to treat patients with inflammatory myopathies and severe dermatologic autoimmune diseases. The FDA has granted fast-track designation for NVG-2089’s development in bullous pemphigoid. This novel, recombinant, non-immunosuppressive immunomodulator targets type II Fc receptors to trigger an endogenous regulatory mechanism that reduces autoimmune dysregulation. The study’s primary objective is to assess the safety and tolerability of NVG-2089, with secondary objectives focusing on pharmacokinetics and pharmacodynamics.
What are the major regional insights for the immunomodulator market, and which region holds the top position?
North America was the largest region in the immunomodulator market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunomodulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Immunomodulator Market Report 2025 Offer?
The immunomodulator market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
An immunomodulator is a substance or medication that modifies or regulates the activity of the immune system. It is used in the treatment of various medical conditions to modify or regulate the activity of the immune system. The specific usage of immunomodulators depends on the underlying condition being treated and the desired effect on the immune response.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15591
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
